INT142735

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2006
Last Reported 2010
Negated 3
Speculated 2
Reported most in Body
Documents 33
Total Number 37
Disease Relevance 45.83
Pain Relevance 11.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
leg 6
foot 1
body 1
RLS (Homo sapiens)
Pain Link Frequency Relevance Heat
Gabapentin 721 100.00 Very High Very High Very High
Pain 100 100.00 Very High Very High Very High
descending inhibitory control 1 100.00 Very High Very High Very High
agonist 306 99.88 Very High Very High Very High
Neuropathic pain 13 99.84 Very High Very High Very High
Dopamine 258 99.60 Very High Very High Very High
carbamazepine 14 99.58 Very High Very High Very High
tolerance 24 99.24 Very High Very High Very High
antagonist 18 99.24 Very High Very High Very High
Opioid 35 98.88 Very High Very High Very High
Disease Link Frequency Relevance Heat
Restless Legs Syndrome 2636 100.00 Very High Very High Very High
Sleep Disorders 372 100.00 Very High Very High Very High
Pain 62 100.00 Very High Very High Very High
Stroke 173 99.92 Very High Very High Very High
Neuropathic Pain 52 99.84 Very High Very High Very High
Migraine Without Aura 4 99.84 Very High Very High Very High
Confusion 10 99.64 Very High Very High Very High
Patent Foramen Ovale 212 99.60 Very High Very High Very High
Mental Disorders 16 99.44 Very High Very High Very High
Anxiety Disorder 41 99.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Sustained resolution of leg restlessness and neuropathic foot dysesthesias also occurred immediately following the neuroma surgery, and she remained completely off neuropsychiatric medication as well as iron and all other drugs known to affect RLS for the next six weeks.
Regulation (affect) of RLS in foot associated with dysesthesia, akathisia, neuropathic pain, neuroma and restless legs syndrome
1) Confidence 0.53 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2949698 Disease Relevance 1.59 Pain Relevance 0.27
These compounds are able to control RLS symptomatology also when present during daytime, but, because of their short half-life, patients should take the medications many times during the day.
Regulation (control) of RLS associated with restless legs syndrome
2) Confidence 0.50 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695234 Disease Relevance 1.10 Pain Relevance 0.22
CONCLUSIONS: Female hormonal changes do not account for the variation in perceived severity in women with RLS during their hormonal milestones and their role in the pathophysiology of RLS is unlikely.


Regulation (role) of RLS
3) Confidence 0.39 Published 2008 Journal Sleep Med. Section Body Doc Link 17921056 Disease Relevance 0.05 Pain Relevance 0
Benzodiazepines, including clonazepam and nitrazepam, are widely prescribed, but their therapeutic effects on RLS symptoms were rather modest.
Regulation (effects) of RLS associated with restless legs syndrome
4) Confidence 0.39 Published 2009 Journal Brain Nerve Section Abstract Doc Link 19514515 Disease Relevance 0.83 Pain Relevance 0.42
Effects of RLS on patients’ mental health
Regulation (Effects) of RLS associated with mental disorders and restless legs syndrome
5) Confidence 0.38 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671952 Disease Relevance 1.78 Pain Relevance 0.10
PURPOSE: The purpose of this study was to evaluate the effects of restless legs syndrome (RLS) on quality of life (QoL), anxiety, and depression in people with type 2 diabetes.
Regulation (effects) of RLS in legs associated with depression, diabetes mellitus, anxiety disorder, restless legs syndrome and sleep disorders
6) Confidence 0.37 Published 2010 Journal Diabetes Educ Section Abstract Doc Link 20185611 Disease Relevance 0.65 Pain Relevance 0.05
However, similarly to RLS, dopaminergic agents are effective in decreasing PLM number.


Regulation (effective) of RLS associated with restless legs syndrome
7) Confidence 0.37 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695234 Disease Relevance 1.19 Pain Relevance 0.35
In order to detect patients affected by a severe form of RLS, physicians should focus their attention on 3 different features of the sleep disorder: intensity, frequency and consequences (sleep quality, daytime tiredness, mood and quality of life) of RLS symptoms.
Regulation (affected) of RLS associated with fatigue, sleep disorders and restless legs syndrome
8) Confidence 0.37 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695234 Disease Relevance 1.61 Pain Relevance 0
CONCLUSION AND PERSPECTIVES: RLS is often underdiagnosed and few subjects receive recommended RLS drug treatment.
Regulation (receive) of RLS associated with restless legs syndrome
9) Confidence 0.37 Published 2009 Journal Rev. Neurol. (Paris) Section Abstract Doc Link 19345965 Disease Relevance 1.54 Pain Relevance 0
Recent investigations support the notion of an alteration of the medial pain pathway as well as of the descending inhibitory control system in restless legs syndrome (RLS), that both involve dopaminergic transmission as well.
Regulation (alteration) of RLS in legs associated with pain, descending inhibitory control, restless legs syndrome and sleep disorders
10) Confidence 0.36 Published 2010 Journal Neurosci. Lett. Section Abstract Doc Link 20184941 Disease Relevance 0.82 Pain Relevance 0.58
An established body of evidence is now gathered from double-blind, placebo-controlled trials providing level 1 evidence that dopamine agonists (DAs) are effective for treatment of RLS and currently should be considered the drug of first choice in most patients (Chaudhuri 2003; DeKokker et al 2005).
Regulation (effective) of RLS in body associated with dopamine, agonist and restless legs syndrome
11) Confidence 0.29 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671772 Disease Relevance 0.74 Pain Relevance 0.19
Apomorphine, a subcutaneously administered nonergot DA, has also been shown to be effective for symptoms of RLS used as an overnight infusion in severe cases (Reuter et al 1999).
Regulation (effective) of RLS associated with restless legs syndrome
12) Confidence 0.29 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671772 Disease Relevance 0.77 Pain Relevance 0.09
The role of modern sedatives such as zolpidem, zopiclone, and zaleplon in the treatment of RLS has not been established to date.


Regulation (role) of RLS associated with restless legs syndrome
13) Confidence 0.29 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671772 Disease Relevance 0.99 Pain Relevance 0.36
Before DAs were available, levodopa was considered effective for RLS, although high rates of augmentation and rebound-related complications have limited the role of levodopa in the treatment of RLS (Allen and Earley 1996; Chaudhuri 2003; DeKokker et al 2005).
Regulation (effective) of RLS associated with agonist and restless legs syndrome
14) Confidence 0.29 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671772 Disease Relevance 0.76 Pain Relevance 0.28
The studies with pramipexole performed in adult patients have clearly shown that the drug is effective in the treatment of RLS in placebo-controlled, double-blind studies (Table 3).
Regulation (controlled) of RLS associated with restless legs syndrome
15) Confidence 0.29 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671938 Disease Relevance 0.90 Pain Relevance 0.23
The studies with pramipexole performed in adult patients have clearly shown that the drug is effective in the treatment of RLS in placebo-controlled, double-blind studies (Table 3).
Regulation (effective) of RLS associated with restless legs syndrome
16) Confidence 0.29 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671938 Disease Relevance 0.90 Pain Relevance 0.23
Patients discontinued all drugs known to affect RLS or sleep for 7 days or more before the baseline visit.
Regulation (affect) of RLS associated with restless legs syndrome
17) Confidence 0.27 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857615 Disease Relevance 1.03 Pain Relevance 0
Gabapentin is an anticonvulsant drug and is approved in the United States for the treatment of postherpetic neuralgia7 and partial seizures.7–10 Gabapentin has also been shown effective in improving RLS symptoms, reducing the frequency of periodic leg movements and improving sleep quality, suggesting a potential role in treating RLS.11–15 Gabapentin is not approved for the indication of RLS treatment, although it is often used off-label for this purpose.5,16,17 Additional placebocontrolled, double-blind clinical trials have also suggested potential uses of gabapentin in the treatment of painful neuropathies in patients with diabetes mellitus18 and anxiety disorders.19
Regulation (indication) of RLS in leg associated with pain, diabetes mellitus, anxiety disorder, anticonvulsant, restless legs syndrome, partial seizures and gabapentin
18) Confidence 0.26 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874339 Disease Relevance 1.31 Pain Relevance 0.89
Clinical trials have shown gabapentin enacarbil to be a safe and effective drug for RLS.
Regulation (effective) of RLS associated with restless legs syndrome and gabapentin
19) Confidence 0.26 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874339 Disease Relevance 1.21 Pain Relevance 1.13
Gabapentin is an anticonvulsant drug and is approved in the United States for the treatment of postherpetic neuralgia7 and partial seizures.7–10 Gabapentin has also been shown effective in improving RLS symptoms, reducing the frequency of periodic leg movements and improving sleep quality, suggesting a potential role in treating RLS.11–15 Gabapentin is not approved for the indication of RLS treatment, although it is often used off-label for this purpose.5,16,17 Additional placebocontrolled, double-blind clinical trials have also suggested potential uses of gabapentin in the treatment of painful neuropathies in patients with diabetes mellitus18 and anxiety disorders.19
Regulation (treating) of RLS in leg associated with pain, diabetes mellitus, anxiety disorder, anticonvulsant, restless legs syndrome, partial seizures and gabapentin
20) Confidence 0.26 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874339 Disease Relevance 1.37 Pain Relevance 0.87

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox